OS Therapies (OSTX) Competitors $1.75 0.00 (0.00%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.74 0.00 (-0.29%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OSTX vs. GNFT, CTMX, EPRX, VTYX, TVGN, CRBU, CYBN, OGI, DMAC, and CRDFShould you be buying OS Therapies stock or one of its competitors? The main competitors of OS Therapies include GENFIT (GNFT), CytomX Therapeutics (CTMX), Eupraxia Pharmaceuticals (EPRX), Ventyx Biosciences (VTYX), Semper Paratus Acquisition (TVGN), Caribou Biosciences (CRBU), Cybin (CYBN), Organigram Global (OGI), DiaMedica Therapeutics (DMAC), and Cardiff Oncology (CRDF). These companies are all part of the "pharmaceutical products" industry. OS Therapies vs. Its Competitors GENFIT CytomX Therapeutics Eupraxia Pharmaceuticals Ventyx Biosciences Semper Paratus Acquisition Caribou Biosciences Cybin Organigram Global DiaMedica Therapeutics Cardiff Oncology OS Therapies (NYSE:OSTX) and GENFIT (NASDAQ:GNFT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends. Is OSTX or GNFT more profitable? Company Net Margins Return on Equity Return on Assets OS TherapiesN/A N/A -569.57% GENFIT N/A N/A N/A Which has preferable valuation & earnings, OSTX or GNFT? GENFIT has higher revenue and earnings than OS Therapies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOS TherapiesN/AN/A-$7.79M-$0.86-2.03GENFIT$76.77M2.48$1.63MN/AN/A Do insiders & institutionals hold more shares of OSTX or GNFT? 2.2% of GENFIT shares are held by institutional investors. 13.8% of OS Therapies shares are held by insiders. Comparatively, 4.2% of GENFIT shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate OSTX or GNFT? OS Therapies presently has a consensus price target of $18.00, suggesting a potential upside of 928.57%. GENFIT has a consensus price target of $13.00, suggesting a potential upside of 241.21%. Given OS Therapies' stronger consensus rating and higher possible upside, equities research analysts clearly believe OS Therapies is more favorable than GENFIT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer OSTX or GNFT? In the previous week, OS Therapies had 2 more articles in the media than GENFIT. MarketBeat recorded 2 mentions for OS Therapies and 0 mentions for GENFIT. GENFIT's average media sentiment score of 0.75 beat OS Therapies' score of 0.20 indicating that GENFIT is being referred to more favorably in the news media. Company Overall Sentiment OS Therapies Neutral GENFIT Positive SummaryOS Therapies beats GENFIT on 6 of the 11 factors compared between the two stocks. Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OSTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OSTX vs. The Competition Export to ExcelMetricOS TherapiesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$49.17M$785.27M$5.48B$20.70BDividend YieldN/A4.84%3.99%3.67%P/E Ratio-2.031.2929.8728.65Price / SalesN/A25.43422.9357.34Price / CashN/A19.5635.9423.59Price / BookN/A6.578.104.32Net Income-$7.79M-$3.92M$3.26B$995.66M7 Day PerformanceN/A-2.83%0.64%1.91%1 Month Performance8.02%-0.30%2.42%-0.54%1 Year Performance-44.44%23.98%27.60%14.76% OS Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OSTXOS Therapies2.2095 of 5 stars$1.75flat$18.00+928.6%-47.8%$49.17MN/A-2.03N/AAnalyst ForecastGap UpHigh Trading VolumeGNFTGENFIT1.7594 of 5 stars$3.79-0.3%$13.00+243.0%-6.2%$190.01M$76.77M0.00120CTMXCytomX Therapeutics4 of 5 stars$2.39+1.7%$5.75+140.6%+81.0%$189.46M$138.10M4.98170News CoverageEPRXEupraxia Pharmaceuticals2.6213 of 5 stars$5.37+2.0%$11.00+105.0%+123.4%$189.15MN/A0.0029VTYXVentyx Biosciences2.5719 of 5 stars$2.72+3.4%$10.00+267.6%+20.4%$187.15MN/A-1.5530News CoverageEarnings ReportUpcoming EarningsTVGNSemper Paratus Acquisition3.6545 of 5 stars$0.99-0.7%$10.00+907.5%+42.7%$183.88MN/A0.003CRBUCaribou Biosciences2.4543 of 5 stars$2.10+7.7%$8.50+304.8%-4.7%$181.36M$9.99M-1.30100Gap UpCYBNCybin2.8614 of 5 stars$7.68+1.6%$85.00+1,006.8%N/A$181.17MN/A-1.7550OGIOrganigram Global1.2517 of 5 stars$1.38+3.8%N/A-5.4%$178.26M$117.47M13.80860Upcoming EarningsGap UpDMACDiaMedica Therapeutics1.4441 of 5 stars$4.36+5.8%$10.75+146.6%+48.3%$176.68MN/A-6.8120CRDFCardiff Oncology1.9979 of 5 stars$2.51-4.9%$11.70+366.1%+12.6%$175.63M$680K-2.8920News CoverageUpcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies GENFIT Competitors CytomX Therapeutics Competitors Eupraxia Pharmaceuticals Competitors Ventyx Biosciences Competitors Semper Paratus Acquisition Competitors Caribou Biosciences Competitors Cybin Competitors Organigram Global Competitors DiaMedica Therapeutics Competitors Cardiff Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OSTX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
